IPP Bureau
Resolution Therapeutics strengthens its team with two new appointments
By IPP Bureau - February 20, 2022
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
GSK pauses phase III RSV maternal vaccine candidate programme
By IPP Bureau - February 20, 2022
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
Merck announces leadership team for human health business
By IPP Bureau - February 20, 2022
In the interim, Deepak Khanna will lead Human Health International.
USFDA lifts clinical hold on submission of Covaxin
By IPP Bureau - February 20, 2022
Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
WHO grants prequalification of Actemra/RoActemra for critical COVID-19 patients
By IPP Bureau - February 20, 2022
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
Moderna expands Its mRNA pipeline with new development programs
By IPP Bureau - February 20, 2022
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
Poxel’s PXL065 granted FDA fast track designation for X-linked adrenoleukodystrophy
By IPP Bureau - February 20, 2022
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Hinduja Global Solutions bags contract from the UK Health Security Agency to provide critical services
By IPP Bureau - February 20, 2022
The partnership is already underway having launched earlier last week, and the contract could be worth up to £211 million.
Aizon’s CEO John Vitalie named one of the top 25 Biotech CEOs of 2022
By IPP Bureau - February 19, 2022
The Healthcare Technology Report provides market research and insights, business news, investment activity updates and important corporate developments related to the healthcare technology sector
cbdMD becomes first American CBD brand to receive UK validation
By IPP Bureau - February 19, 2022
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
Fitch revises outlook on Jubilant Pharma to negative; affirms at 'BB'
By IPP Bureau - February 19, 2022
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Jagsonpal Pharma inks agreement with Suvinys Developers
By IPP Bureau - February 19, 2022
Suvinys Developers will supply dydrogesterone to Jagsonpal Pharma as per the terms and conditions mentioned in the agreement.
Amneal expands injectables portfolio with four new products
By IPP Bureau - February 19, 2022
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
Piramal Pharma appoints Amyra Dastur as brand ambassador for lacto calamine range
By IPP Bureau - February 19, 2022
The brand has added a range of exciting new products especially formulated for oily skin.
Tremfya achieves greater clinical responses in patients with ulcerative colitis
By IPP Bureau - February 19, 2022
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
